Systems pharmacology to predict drug toxicity: Integration across levels of biological organization

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 451-473

  Bai, Jane P F ^a   Abernethy, Darrell R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

adverse drug effects; bioinformatics; systems analysis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; BETA 2 MICROGLOBULIN; CISPLATIN; CLOZAPINE; CYSTATIN C; DRUG METABOLITE; FLUCLOXACILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; N ACETYL 4 BENZOQUINONE IMINE; NATRIURETIC FACTOR; PARACETAMOL; SEROTONIN 2C RECEPTOR; TETRACYCLINE; TROGLITAZONE; TROPONIN T; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; BIOINFORMATICS; BONE MARROW SUPPRESSION; COMPUTER SYSTEM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG APPROVAL; DRUG DATABASE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRUG TOXICITY; FATTY LIVER; GENOMICS; HUMAN; LIVER TOXICITY; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHARMACOLOGICAL SCIENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEQUENCE ANALYSIS; SYSTEM ANALYSIS; SYSTEMS PHARMACOLOGY; TOXIC HEPATITIS; TOXICITY TESTING; TRANSCRIPTOMICS;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; PHARMACOLOGY; SYSTEMS BIOLOGY;

EID: 84872243783     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140248     Document Type: Review

References (144)

1. Schadt EE, Friend SH, Shaywitz DA. 2009. A network view of disease and compound screening. Nat. Rev. Drug Discov. 8:286-95
2. US Food Drug Admin. 2012. Drugs@FDA: FDA Approved Drug Products. Silver Spring, MD: US Food Drug Admin. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm
3. US Food Drug Admin. 2012. Adverse Event Reporting System (AERS ). Silver Spring, MD: US Food Drug Admin. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default. htm
4. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711-15
5. Haouzi D, Cohen I, Vieira HL, Poncet D, Boya P, et al. 2002. Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo. Apoptosis 7:395-405
6. Reid AB, Kurten RC, McCullough SS, Brock RW, Hinson JA. 2005. Mechanisms of acetaminopheninduced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J. Pharmacol. Exp. Ther. 312:509-16
7. Bae MA, Pie JE, Song BJ. 2001. Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH2-terminal protein kinase-related cell death pathway. Mol. Pharmacol. 60:847-56
8. Bechmann LP, Marquitan G, Jochum C, Saner F, Gerken G, Canbay A. 2008. Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-onchronic liver failure. Liver Int. 28:713-16
9. Bender A, Jenkins JL, Scheiber J, Sukuru SC, Glick M, Davies JW. 2009. How similar are similarity searching methods? A principal component analysis of molecular descriptor space. J. Chem. Inf. Model. 49:108-19
10. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. 2006. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science 313:1929-35
11. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. 2008. Drug target identification using side-effect similarity. Science 321:263-66
12. Takarabe M, Shigemizu D, Kotera M, Goto S, Kanehisa M. 2010. Characterization and classification of adverse drug interactions. Genome Inform. 22:167-75
13. Keiser MJ, Irwin JJ, Shoichet BK. 2010. The chemical basis of pharmacology. Biochemistry 49:10267-76
14. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, et al. 2009. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 49:308-17
15. Kanehisa Lab. 2012. KEGG: Kyoto Encyclopedia of Genes and Genomes. Kyoto: Kyoto Univ. http://www.genome.jp/kegg/
16. Daly AK. 2012. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52:21-35
17. Rager JE, Smeester L, Jaspers I, Sexton KG, Fry RC. 2011. Epigenetic changes induced by air toxics: Formaldehyde exposure alters miRNA expression profiles in human lung cells. Environ. Health Perspect. 119:494-500
18. Shah AD, Wood DM, Dargan PI. 2011. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. Br. J. Clin. Pharmacol. 71:20-28
19. Fannin RD, Russo M, O'Connell TM, Gerrish K, Winnike JH, et al. 2010. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 51:227-36
20. US Dep. Health Hum. Serv., US Food Drug Admin., Cent. Drug Eval. Res., Cent. Biol. Eval. Res. 2009. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Silver Spring, MD: US Food Drug Admin. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf
21. Sodhi MS, Airey DC, Lambert W, Burnet PW, Harrison PJ, Sanders-Bush E. 2005. A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol. Pharmacol. 68:711-19
22. Liu Y, Balaraman Y, Wang G, Nephew KP, Zhou FC. 2009. Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation. Epigenetics 4:500-11
23. Xie L, Li J, Bourne PE. 2009. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput. Biol. 5:e1000387
24. Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK. 2010. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol. Cell. Proteomics 9:1849-65
25. Antherieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA. 2011. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 53:1895-905
26. Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ. 2009. Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARα activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol. 22:699-707
27. Julie NL, Julie IM, Kende AI, Wilson GL. 2008. Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone. Diabetologia 51:2108-16
28. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. 2010. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6:343
29. Hauben M, Aronson JK. 2009. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 32:99-110
30. Szarfman A, Machado SG, O'Neill RT. 2002. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25:381-92
31. Lempiainen H, Muller A, Brasa S, Teo SS, Roloff TC, et al. 2011. Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS ONE 6:e18216
32. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. 2011. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29:1039-45
33. Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. 2011. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ. Res. 109:1401-9
34. Padala S, Thompson PD. 2012. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 222:15-21
35. Fliri AF, Loging WT, Thadeio PF, Volkmann RA. 2005. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1:389-97
36. Yamanishi Y, Kotera M, Kanehisa M, Goto S. 2010. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26:i246-54
37. She X, Rohl CA, Castle JC, Kulkarni AV, Johnson JM, Chen R. 2009. Definition, conservation and epigenetics of housekeeping and tissue-enriched genes. BMC Genomics 10:269
38. Hansch C, Leo A. 1979. Substituent Constants for Correlation Analysis in Chemistry and Biology. New York: Wiley
39. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. 2009. Predicting new molecular targets for known drugs. Nature 462:175-81
40. ClarkM, Wiseman JS. 2009. Fragment-based prediction of the clinical occurrence of longQTsyndrome and torsade de pointes. J. Chem. Inf. Model. 49:2617-26
41. Hammann F, Gutmann H, Vogt N, Helma C, Drewe J. 2010. Prediction of adverse drug reactions using decision tree modeling. Clin. Pharmacol. Ther. 88:52-59
42. Rodgers AD, Zhu H, Fourches D, Rusyn I, Tropsha A. 2010. Modeling liver-related adverse effects of drugs using k nearest neighbor quantitative structure-activity relationship method. Chem. Res. Toxicol. 23:724-32
43. Cami A, Arnold A, Manzi S, Reis B. 2011. Predicting adverse drug events using pharmacological network models. Sci. Transl. Med. 3:114ra27
44. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, et al. 2007. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2:861-73
45. Low Y, Uehara T, Minowa Y, Yamada H, Ohno Y, et al. 2011. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem. Res. Toxicol. 24:1251-62
46. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, et al. 2008. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol. Mech. Methods 18:217-27
47. Freimer N, Sabatti C. 2003. The human phenome project. Nat. Genet. 34:15-21
48. Butte AJ, Kohane IS. 2006. Creation and implications of a phenome-genome network. Nat. Biotechnol. 24:55-62
49. Bilder RM. 2008. Phenomics: building scaffolds for biological hypotheses in the post-genomic era. Biol. Psychiatry 63:439-40
50. Scott NJ, Cameron VA, Raudsepp S, Lewis LK, Simpson ER, et al. 2012. Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice. Am. J. Physiol. Endocrinol. Metab. 302:E576-84
51. Harrill AH, Ross PK, Gatti DM, Threadgill DW, Rusyn I. 2009. Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel. Toxicol. Sci. 110:235-43
52. Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, et al. 2008. Deletion of apoptosis signalregulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-JunN-terminal kinase activation. Gastroenterology 135:1311-21
53. Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, et al. 2009. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res. 19:1507-15
54. Cai S, Wang H, Bailey B, Ernstberger A, Juliar BE, et al. 2011. Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin. Cancer Res. 17:2195-206
55. Chen AA, Thomas DK, Ong LL, Schwartz RE, Golub TR, Bhatia SN. 2011. Humanized mice with ectopic artificial liver tissues. Proc. Natl. Acad. Sci. USA 108:11842-47
56. Strom SC, Davila J, Grompe M. 2010. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol. Biol. 640:491-509
57. DiBlasio-Smith EA, Arai M, Quinet EM, Evans MJ, Kornaga T, et al. 2008. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J. Transl. Med. 6:59
58. Shukla SJ, Huang R, Austin CP, Xia M. 2010. The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov. Today 15:997-1007
59. Uehara T, Ono A, Maruyama T, Kato I, Yamada H, et al. 2010. The Japanese Toxicogenomics Project: application of toxicogenomics. Mol. Nutr. Food Res. 54:218-27
60. Bartfai T, Buckley PT, Eberwine J. 2012. Drug targets: single-cell transcriptomics hastens unbiased discovery. Trends Pharmacol. Sci. 33:9-16
61. Yilmaz S, Boffito M, Collot-Teixeira S, De Lorenzo F, Waters L, et al. 2010. Investigation of lowdose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays. Genomics 96:57-65
62. Erler JT, Linding R. 2010. Network-based drugs and biomarkers. J. Pathol. 220:290-96
63. Zhao Y, Widen SG, Jamaluddin M, Tian B, Wood TG, et al. 2011. Quantification of activated NF-κB/RelA complexes using ssDNA aptamer affinity-stable isotope dilution-selected reaction monitoringmass spectrometry. Mol. Cell. Proteomics 10:M111.008771
64. Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL. 2008. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann. Oncol. 19:1417-22
65. Liu G, Kolesar J, McNeel DG, Leith C, Schell K, et al. 2008. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin. Cancer Res. 14:2732-39
66. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. 2011. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3:96ra77
67. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, et al. 2011. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3:96ra76
68. Bao N, Lye KW, Barton MK. 2004. MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome. Dev. Cell 7:653-62
69. Tuddenham L, Wheeler G, Ntounia-Fousara S, Waters J, Hajihosseini MK, et al. 2006. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett. 580:4214-17
70. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al. 2006. Specific activation ofmicroRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-43
71. Jetten MJ, Gaj S, Ruiz-Aracama A, de Kok TM, van Delft JH, et al. 2012. 'Omics analysis of low dose acetaminophen intake demonstrates novel response pathways in humans. Toxicol. Appl. Pharmacol. 259(3):320-28
72. Fukushima T, Hamada Y, Yamada H, Horii I. 2007. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride- regulating role of micro-RNA for RNA expression. J. Toxicol. Sci. 32:401-9
73. Lizarraga D, Gaj S, Brauers KJ, Timmermans L, Kleinjans JC, van Delft JH. 2012. Benzo[a]pyreneinduced changes in microRNA-mRNA networks. Chem. Res. Toxicol. 25:838-49
74. Wilson KD, Hu S, Venkatasubrahmanyam S, Fu JD, Sun N, et al. 2010. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ. Cardiovasc. Genet. 3:426-35
75. Levanon EY, Eisenberg E, Yelin R, Nemzer S, Hallegger M, et al. 2004. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 22:1001-5
76. Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, et al. 2001. RNA editing of the human serotonin 5-HT2C receptor: alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology: 24:478-91
77. Bae MA, Song BJ. 2003. Critical role of c-Jun N-terminal protein kinase activation in troglitazoneinduced apoptosis of human HepG2 hepatoma cells. Mol. Pharmacol. 63:401-8
78. Tyagi M, Hashimoto K, Shoemaker BA, Wuchty S, Panchenko AR. 2012. Large-scale mapping of human protein interactome using structural complexes. EMBO Rep. 13:266-71
79. Fliri AF, Loging WT, Volkmann RA. 2009. Drug effects viewed from a signal transduction network perspective. J. Med. Chem. 52:8038-46
80. Sarkar IN, Butte AJ, Lussier YA, Tarczy-Hornoch P, Ohno-Machado L. 2011. Translational bioinformatics: linking knowledge across biological and clinical realms. J. Am. Med. Inform. Assoc. 18:354-57
81. Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E. 2010. Drug discovery in a multidimensional world: systems, patterns, and networks. J. Cardiovasc. Transl. Res. 3:438-47
82. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, et al. 2007. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. USA 104:1777-82
83. Cosgrove BD, Alexopoulos LG, Hang TC, Hendriks BS, Sorger PK, et al. 2010. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol. BioSyst. 6:1195-206
84. Luo H, Chen J, Shi L, Mikailov M, Zhu H, et al. 2011. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 39:W492-98
85. Yang L, Chen J, He L. 2009. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput. Biol. 5:e1000441
86. Yang L, Wang K, Chen J, Jegga AG, Luo H, et al. 2011. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome-clozapine-induced agranulocytosis as a case study. PLoS Comput. Biol. 7:e1002016
87. Wallach I, Jaitly N, Lilien R. 2010. A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS ONE 5:e12063
88. Yang X, Huang Y, Crowson M, Li J, Maitland ML, Lussier YA. 2010. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43:376-84
89. Berger SI, Ma'ayan A, Iyengar R. 2010. Systems pharmacology of arrhythmias. Sci. Signal. 3:ra30
90. Moro S, Chipman JK, Antczak P, Turan N, Dekant W, et al. 2012. Identification and pathway mapping of furan target proteins reveal mitochondrial energy production and redox regulation as critical targets of furan toxicity. Toxicol. Sci. 126:336-52
91. Fulgencio JP, Kohl C, Girard J, Pegorier JP. 1996. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45:1556-62
92. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, et al. 1995. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metabolism 44:1626-30
93. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, et al. 2008. Large-scale chemical dissection of mitochondrial function. Nat. Biotechnol. 26:343-51
94. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, et al. 1981. Sequence and organization of the human mitochondrial genome. Nature 290:457-65
95. Edling Y, Sivertsson LK, Butura A, Ingelman-Sundberg M, Ek M. 2009. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol. In Vitro 23:1387-95
96. Heydarkhan-Hagvall S, Helenius G, Johansson BR, Li JY, Mattsson E, Risberg B. 2003. Co-culture of endothelial cells and smooth muscle cells affects gene expression of angiogenic factors. J. Cell. Biochem. 89:1250-59
97. LaFramboise WA, Scalise D, Stoodley P, Graner SR, Guthrie RD, et al. 2007. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am. J. Physiol. Cell Physiol. 292:C1799-808
98. Prot JM, Briffaut AS, Letourneur F, Chafey P, Merlier F, et al. 2011. Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip. PLoS ONE 6:e21268
99. Khetani SR, Bhatia SN. 2008. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26:120-26
100. Shintu L, Baudoin R, Navratil V, Prot JM, Pontoizeau C, et al. 2012. Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. Anal. Chem. 84:1840-48
101. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. 2010. Reconstituting organ-level lung functions on a chip. Science 328:1662-68
102. Santostefano MJ, Richardson VM, Walker NJ, Blanton J, Lindros KO, et al. 1999. Dose-dependent localization of TCDD in isolated centrilobular and periportal hepatocytes. Toxicol. Sci. 52:9-19
103. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. 2010. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol. Appl. Pharmacol. 242:38-46
104. Vickers AE. 2009. Tissue slices for the evaluation of metabolism-based toxicity with the example of diclofenac. Chem. Biol. Interact. 179:9-16
105. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. 2011. Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab. Dispos. 39:1440-50
106. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, et al. 1999. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 17:2237-43
107. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, et al. 2007. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 50:1973-80
108. Grams ME, Rabb H. 2012. The distant organ effects of acute kidney injury. Kidney Int. 81:942-48
109. Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, et al. 2012. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am. J. Kidney Dis. 59:653-62
110. Merrill GF, Kurth EJ, Hardie DG, Winder WW. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.Am. J. Physiol. Endocrinol.Metab. 273:E1107-12
111. Song Z, Deaciuc I, Zhou Z, Song M, Chen T, et al. 2007. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 293:G894-902
112. Decleves AE, Mathew AV, Cunard R, Sharma K. 2011. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol. 22:1846-55
113. Zoccali C, Mallamaci F, Panuccio V, TripepiG, Cutrupi S, et al. 2003. Adiponectin ismarkedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int. Suppl. 84:S98-102
114. Tujios S, Fontana RJ. 2011. Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 8:202-11
115. Int. Conf. Harmon. 2005. E2B(R) clinical safety data management: data elements for transmission of individual case safety reports, revision 2. Silver Spring, MD: US Food Drug Admin. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm129399.pdf
116. Funk C, Ponelle C, Scheuermann G, Pantze M. 2001. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59:627-35
117. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. 2006. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131:165-78
118. Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. 2006. Paracetamol induced hepatotoxicity. Arch. Dis. Child. 91:598-603
119. Russmann S, Kaye JA, Jick SS, Jick H. 2005. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60:76-82
120. Li X, Li C, Shang D, Li J, Han J, et al. 2011. The implications of relationships between human diseases and metabolic subpathways. PLoS ONE 6:e21131
121. Chang RL, Xie L, Bourne PE, Palsson BO. 2010. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput. Biol. 6:e1000938
122. Jupp S, Klein J, Schanstra J, Stevens R. 2011. Developing a kidney and urinary pathway knowledge base. J. Biomed. Semantics 2(Suppl. 2):S7
123. Rogue A, Lambert C, Josse R, Antherieu S, Spire C, et al. 2011. Comparative gene expression profiles induced by PPARγand PPARα/γagonists in human hepatocytes. PLoS ONE 6:e18816
124. VallierL, Touboul T, Brown S, Cho C, Bilican B, et al. 2009. Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. Stem Cells 27:2655-66
125. Bilder RM, Sabb FW, Cannon TD, London ED, Jentsch JD, et al. 2009. Phenomics: the systematic study of phenotypes on a genome-wide scale. Neuroscience 164:30-42
126. Shah NH, Jonquet C, Chiang AP, Butte AJ, Chen R, Musen MA. 2009. Ontology-driven indexing of public datasets for translational bioinformatics. BMC Bioinform. 10(Suppl. 2):S1
127. Shah NH, Bhatia N, Jonquet C, Rubin D, Chiang AP, Musen MA. 2009. Comparison of concept recognizers for building the Open Biomedical Annotator. BMC Bioinform. 10(Suppl. 9):S14
128. Hur J, Xiang Z, Feldman EL, He Y. 2011. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunol. 12:49
129. Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN Jr, Boyer JL. 2006. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol. Sci. 92:587-95
130. Morgan AA, Chen R, Butte AJ. 2010. Likelihood ratios for genome medicine. Genome Med. 2:30
131. Mudd PN Jr, Groenendaal H, Bush MA, Schmith VD. 2010. Probabilistic risk analysis: improving early drug development decision making. Clin. Pharmacol. Ther. 88:871-75
132. Barz S, Kashefi E, Broadbent A, Fitzsimons JF, Zeilinger A, Walther P. 2012. Demonstration of blind quantum computing. Science 335:303-8
133. Chouvarine P, Cooksey AM, McCarthy FM, Ray DA, Baldwin BS, et al. 2012. Transcriptome-based differentiation of closely-related Miscanthus lines. PLoS ONE 7:e29850
134. Gopalakrishnan V, Lustgarten JL, Visweswaran S, CooperGF. 2010. Bayesian rule learning for biomedical data mining. Bioinformatics 26:668-75
135. Maddatu TP, Grubb SC, Bult CJ, Bogue MA. 2012. Mouse Phenome Database (MPD). Nucleic Acids Res. 40:D887-94
136. Sardana D, Vasa S, Vepachedu N, Chen J, Gudivada RC, et al. 2010. PhenoHM: human-mouse comparative phenome-genome server. Nucleic Acids Res. 38:W165-74
137. Curtis RE, Yin J, Kinnaird P, Xing EP. 2012. Finding genome- transcriptome-phenome association with structured association mapping and visualization in GenAMap. Pac. Symp. Biocomput. 2012:327-38
138. Gormanns P, Mueller NS, Ditzen C, Wolf S, Holsboer F, Turck CW. 2011. Phenome-transcriptome correlation unravels anxiety and depression related pathways. J. Psychiatr. Res. 45:973-79
139. Hoehndorf R, Schofield PN, Gkoutos GV. 2011. PhenomeNET: a whole-phenome approach to disease gene discovery. Nucleic Acids Res. 39:e119
140. Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, et al. 2011. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet. 7:e1002322
141. Hoehndorf R, Oellrich A, Rebholz-Schuhmann D, Schofield PN, Gkoutos GV. 2012. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing. Pac. Symp. Biocomput. 2012:388-99
142. Friend SH. 2010. The need for precompetitive integrative bionetwork disease model building. Clin. Pharmacol. Ther. 87:536-39
143. McBurney RN, Hines WM, Von Tungeln LS, Schnackenberg LK, Beger RD, et al. 2009. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol. Pathol. 37:52-64
144. Suter L, Schroeder S, Meyer K, Gautier JC, Amberg A, et al. 2011. EU framework 6 project: Predictive Toxicology (PredTox)-overview and outcome. Toxicol. Appl. Pharmacol. 252:73-84